

# RELATIVITY-047 5-year data: Choosing the right path for your patients with advanced melanoma



10:30–11:30

Thursday 11<sup>th</sup> June

This Bristol Myers Squibb sponsored promotional symposium is intended for UK healthcare professionals only.



**Dr Rebecca Lee (Chair)**  
Consultant Medical  
Oncologist and Wellcome  
early career fellow,  
The Christie NHS Foundation  
Trust



**Prof. Anna Olsson-Brown**  
Consultant Medical  
Oncologist and SACT Lead,  
Surrey and Sussex Cancer  
Alliance, Immuno-Oncology  
Clinical Network



**Deirdre Stapleton**  
Cancer Nurse Specialist  
University Hospitals  
Plymouth NHS Trust

## Don't miss out

Scan the QR for BMS ePermissions  
to consent to receiving updates  
about other educational events



To access additional resources,  
join the BMS I-O Academy  
promotional website:

<https://www.bms-io-academy.co.uk/home>

For HCPs based in GB only

OPDUALAG (nivolumab/relatlimab) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older<sup>1</sup>

Prescribing and adverse events reporting information is available [at this link](#) or from a BMS representative.

1. OPDUALAG Summary of Product Characteristics. Accessed June 2026.

